Inactive Instrument

Other languages Signal Genetics Inc Nasdaq

Equities

US8266401046

End-of-day quote Nasdaq Other stock markets
- ^USD	-

Apr. 16	Foghorn Therapeutics Names Kristian Humer CFO	MT
Mar. 21	B. Riley Lowers Viridian Therapeutics' PT to $25 From $29, Keeps Buy Rating; Adjusts Model to Reflect Recent Equity Offering, Quarterly Numbers	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Viridian Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27
Viridian Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27
Viridian Therapeutics Names Jennifer Tousignant as Chief Legal Officer	Feb. 16
Viridian Therapeutics, Inc. Appoints Jennifer Tousignant as Chief Legal Officer	Feb. 16
Viridian Therapeutics Prices Common Stock Offering at $21 per Share	Jan. 18
Viridian Therapeutics Starts Underwritten Stock Offering; Shares Fall After Hours	Jan. 17
Viridian Therapeutics, Inc. Provides Key Updates on its Anti-Insulin-Like Growth Factor 1 Receptor (IGF-1R) Programs in Thyroid Eye Disease and its Programs Targeting FcRn	Jan. 08
Viridian Therapeutics, Inc. Announces Executive Changes	Jan. 08
Viridian Therapeutics Q3 Loss Widens, Revenue Drops	Nov. 13
Viridian Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Viridian Therapeutics, Inc. Announces the Resignation of Scott Myers as a Member of the Board of Directors	Nov. 02
Viridian Therapeutics Names Stephen Mahoney Chief Executive	23-10-30
Viridian Therapeutics, Inc. Appoints Thomas Beetham as Chief Operating Officer	23-10-30
Viridian Therapeutics, Inc. Announces Management Changes	23-10-30
Viridian Therapeutics, Inc. Appoints Stephen Mahoney as Chief Executive Officer	23-10-30
Ypsomed to Customize, Supply Autoinjector Pen Device for Viridian Therapeutics	23-10-26
Ypsomed geht Partnerschaft mit Viridian Therapeutics ein	23-10-26
Viridian Therapeutics, Inc. Appoints Sarah Gheuens to its Board of Directors	23-09-25
Viridian Therapeutics, Inc. Announces Executive Changes	23-09-12
Viridian Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Signal Genetics Inc Nasdaq

Equities

US8266401046

Other languages

Filters